Get the Stockscreener App
11.98
1.24%
-0.15
After Hours:
12.10
0.12
+1.00%
Tenax Therapeutics Inc stock is traded at $11.98, with a volume of 351.78K.
It is down -1.24% in the last 24 hours and down -16.22% over the past month.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
See More
Previous Close:
$12.13
Open:
$12.35
24h Volume:
351.78K
Relative Volume:
0.70
Market Cap:
$317.77M
Revenue:
-
Net Income/Loss:
$-52.60M
P/E Ratio:
-8.9664
EPS:
-1.3361
Net Cash Flow:
$-35.80M
1W Performance:
+4.40%
1M Performance:
-16.22%
6M Performance:
+26.50%
1Y Performance:
+98.06%
1-Day Range:
$11.95
$12.45
1-Week Range:
$11.51
$12.75
52-Week Range:
$5.34
$18.38
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
11.98 | 321.75M | 0 | -52.60M | -35.80M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Tenax Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Clinical DevelopmentEarnings Call Q&A - Newser
Tenax Therapeutics (TENX) Faces Resistance Test After 1.86% Pullback From Recent HighsShared Trade Alerts - Newser
What's Driving Tenax Therapeutics' Recent Surge - Kavout
Millennium Group (TENX) reports 1,347,130 shared votes, 5.1% stake - Stock Titan
Tectonic Therapeutics: Currently In A Catalyst Vacuum (NASDAQ:TECX) - Seeking Alpha
Understanding Momentum Shifts in (TENX) - Stock Traders Daily
LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure - Stock Titan
Stonepine holds 975,200 shares in Tenax Therapeutics (NASDAQ: TENX), 3.7% stake - Stock Titan
VHCP group discloses 9.99% stake in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
Point72 group discloses 533,965 shares in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
BVF affiliates hold warrants convertible into TENX shares (NASDAQ: TENX) constrained by 9.99% blocker - Stock Titan
Perceptive Advisors (NASDAQ: TENX) reports 1.45M-share position - Stock Titan
About Us - FinancialContent
Tenax Therapeutics (TENX) Stock: Consolidating at $$11.93 — Next Move Ahead 2026-05-15Insider Buying - Newser
Dellora holds ~394,665 shares in TENX (Nasdaq: TENX) per amended 13G/A - Stock Titan
RTW Investments (TENX) reports 9.99% stake in Tenax Therapeutics - Stock Titan
Tenax Therapeutics (TENX) Stalls at $$11.94 — Consolidation Phase 2026-05-14Growth Factor - Newser
Tenax Therapeutics (NASDAQ: TENX) awards CFO 10K shares and 450K options - Stock Titan
TENAX THERAPEUTICS (TENX) CFO files Form 3 showing zero Common Stock owned - Stock Titan
Phase 3 spending lifts Tenax (NASDAQ: TENX) Q1 loss but extends runway - Stock Titan
TradingKey - TradingKey
Tenax Therapeutics Announces Q1 2026 Results, Advances Phase 3 LEVEL Study for TNX-103 and Expands Leadership Team - Minichart
Tenax Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
A Look at Tenax Therapeutics (TENX) Valuation After Q1 2026: EPS - GuruFocus
Tenax Therapeutics (TENX) Shares Updates on TNX-103 Phase 3 Stud - GuruFocus
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
Tenax Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tenax Therapeutics (NASDAQ:TENX) Q1 2026 Slightly Beats EPS, Gears Up for Pivotal Phase 3 Data in Q3 - ChartMill
Tenax Therapeutics (NASDAQ: TENX) boosts Phase 3 spend, extends cash runway - Stock Titan
TENAX THERAPEUTICS ($TENX) Releases Q1 2026 Earnings - Quiver Quantitative
Tenax Therapeutics: Q1 Earnings Snapshot - Barchart.com
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
William Blair Maintains Tenax Therapeutics(TENX.US) With Buy Rating - Moomoo
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | TENX Stock News - GuruFocus
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Tenax uses stock options to hire 4 staff in clinical and commercial roles - Stock Titan
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - Weekly Voice
Avoiding Lag: Real-Time Signals in (TENX) Movement - Stock Traders Daily
T. Rowe Price (TENX) reports 2.84M shares, 11.0% stake in Tenax - Stock Titan
T. Rowe Price (NASDAQ: TENX) holds 2.95M shares, 17.2% disclosed - Stock Titan
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
TENX SEC FilingsTenax Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Tenax Therapeutics names Timothy Healey as chief commercial officer By Investing.com - Investing.com Australia
Invus affiliates disclose 2.1% stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer - Investing News Network
Tenax Therapeutics names Timothy Healey as chief commercial officer - Investing.com
Tenax brings in drug launch veteran Timothy Healey to prep TNX-103 - Stock Titan
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenax Therapeutics Inc Stock (TENX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):